Skip to main content
. 2023 Oct 19;15(10):5534–5548. doi: 10.21037/jtd-23-125

Figure 1.

Figure 1

Flow chart. (A) Design of the study. From the establishment of a clinical cohort to the collection, treatment and analysis of serum and then to the follow-up of those patients upon PC treatment. (B) Scheme to screen specific diagnostic biomarkers for PC. PC, patients with pulmonary cryptococcosis; UHPLC-MS, ultra high performance liquid chromatography-mass spectrometry technology; MRM, multiple reaction monitoring; OPLS-DA, orthogonal partial least squares discriminate analysis; VIP, variable importance in the projection; AUC, area under curve; PA, patients with pulmonary aspergillosis; TB, patients with pulmonary tuberculosis; SPL, sphingolipid.